SHANGHAI – In its third academic collaboration deal announced in China this year, Astrazeneca plc, of London, signed a translational research agreement with scientists from Tianjin Medical University (TMU) to explore novel targets for cardiac fibrosis, important in the area of cardiovascular disease (CVD).